PharmaDesign, Euroscreen Sign Agreement on Joint Research for Peptide Ligands for GPCRs.Tokyo, Japan, Jan 5, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - PharmaDesign announced on January 5 that it has signed a joint research agreement with Euroscreen SA regarding G-protein-coupled receptors. Under the agreement terms, the two companies will combine their expertise, namely peptides chemically synthesized syn·the·sized adj. 1. Relating to or being an instrument whose sound is modified or augmented by a synthesizer. 2. Relating to or being compositions or a composition performed on synthesizers or synthesized instruments. by PharmaDesign and Euroscreen's techniques for functional screening and pharmaceutical analysis, and strive to search and identify endogenous endogenous /en·dog·e·nous/ (en-doj´e-nus) produced within or caused by factors within the organism. en·dog·e·nous adj. 1. Originating or produced within an organism, tissue, or cell. peptide ligands and receptors for orphan orphan: see adoption; foundling hospital; guardian and ward. See widow & orphan. Orphan See also Abandonment. Adverse, Anthony finally, at middle age, discovers origins. [Am. Lit. G-protein-coupled receptors (GPCRs). Through this collaboration, the partners aim to contribute to further development in the drug discovery field. Euroscreen SA, headquartered in Brussels, is a leading company in the field of GPCRs. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion